Found 3 clinical trials
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not …
- 144 views
- 21 Jun, 2021
- 25 locations
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1
Vismodegib (ERIVEDGE) at the standard dose of 150 mg/day orally is indicated for the treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects. Cramps
- 0 views
- 01 Feb, 2021
- 1 location
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
The primary objectives are to: Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell
- 0 views
- 25 Jan, 2021
- 1 location